Dr. Clay Siegall went through the University of Maryland from where he was awarded a degree B.S degree in Zoology upon his graduation. He later went further his education at George Washington University from where he earned a Ph.D. in Genetics.
Dr. Clay Siegall has dedicated his career to the research of cancer and the development of its therapy. He is currently heading the way to the treatment of cancer by use of drugs. Most of his time is spent in the medical field in endeavors to come up with the best solution to cancer. With the support of Seattle Genetics Company is commitment in adding more effective and affordable drugs to cure cancer. Dr. Siegall joined the Mirna’s board of directors a company to share his broad experience and achievements in developing the microRNA-based therapeutics.
Dr. Clay Siegall is one of the founders to Seattle Genetics, a biotechnology company established in1998. Dr. Clay Siegall is currently working with the Company in the board of directors as their Chairman, as the Company’ President and as the CEO. Dr. Siegall have played very critical roles in directing the Company towards the achievement of its goals. He guided the Company into activities that greatly raised the company’s capital to over 670 million dollars. In 2011, the Administration of Drug and Food in the United States approved the drugs produced by the Settle Genetics. The company has been making numerous therapies for the cancer basing their principle on antibodies.
Dr. Siegall has also taken the cancer therapy into the literature fields by publishing over 70 works and 15 patents. Other than Mirna and Seattle Genetics, Dr. Siegall has worked with several other medical institutions as a member and also in the top management position. Some of the Institutions include the Washington Biotechnology where he served in the board of Directors, Biomedical Association and also at the Alder Biopharmaceuticals, a private company where he is currently serving as a member of their Board of Directors.